Notice of NIAID Participation in RFA-HL-26-017, Catalyze: Product Definition for Small Molecules, Biologics and Combination Products-Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33)

In Vivo. 2026 May-Jun;40(3):1317-1326. doi: 10.21873/invivo.14285.ABSTRACTBACKGROUND/AIM: Pain assessment and management in children remain challenging, particularly in those with neurodevelopmental disorders. Attention-deficit/hyperactivity disorder (ADHD) is characterized by alterations in attention, executive function, emotional regulation, and reward processing. These domains are also critical